User profiles for Elizabeth G.E. de Vries

Elisabeth de Vries

Professor of Medical Oncology, University Medical Center Groningen, Groningen, the …
Verified email at umcg.nl
Cited by 108199

89Zr-bevacizumab PET: potential early indicator of everolimus efficacy in patients with metastatic renal cell carcinoma

…, MN Lub-de Hooge, EGE de Vries… - Journal of Nuclear …, 2017 - Soc Nuclear Med
Currently, biomarkers that predict the efficacy of everolimus in metastatic renal cell carcinoma
(mRCC) patients are lacking. Everolimus inhibits vascular endothelial growth factor A (…

[PDF][PDF] Feasibility of tumor imaging using l-3-[iodine-123]-iodo-α-methyl-tyrosine in extracranial tumors

…, HJ Hoekstra, HJM Groen, EGE de Vries… - Journal of Nuclear …, 1998 - Soc Nuclear Med
MATERIALS AND METhODS Patients Twenty patients (10 male, 10 female; age range 23—
81yr; mean age 61yr), with known or suspected malignancies, were recruited randomly …

[HTML][HTML] ESMO/ASCO recommendations for a global curriculum in medical oncology edition 2016

…, S Coupland, L De Petris, M De Santis, EGE De Vries… - ESMO open, 2016 - Elsevier
The European Society for Medical Oncology (ESMO) and the American Society of Clinical
Oncology (ASCO) are publishing a new edition of the ESMO/ASCO Global Curriculum (GC) …

[CITATION][C] Zirconium-89-trastuzumab positron emission tomography as a tool to solve a clinical dilemma in a patient with breast cancer

…, MN Lub-de Hooge, EGE de Vries… - Journal of Clinical …, 2012 - ascopubs.org
Discussion When metastases of breast cancer are suspected, standard workup consists of a
CT scan of the chest and abdomen and a bone scan. In clinical situations in which other …

Comparative assessment of clinical benefit using the ESMO-magnitude of clinical benefit scale version 1.1 and the ASCO value framework net health benefit score

NI Cherny, EGE De Vries, U Dafni… - Journal of Clinical …, 2019 - research.rug.nl
PURPOSE To better understand the European Society for Medical Oncology-Magnitude of
Clinical Benefit Scale version 1.1 (ESMO-MCBS v1. 1) and the ASCO Value Framework Net …

Increased cancer risk after liver transplantation: a population-based study

…, M Schaapveld, AP van den Berg, EGE de Vries… - Journal of …, 2001 - Elsevier
Background/Aims: Development of de novo malignancies emerges as a serious long term
complication after liver transplantation. Methods: We reviewed the medical records of 174 …

Immune modulation therapy and imaging: workshop report

…, LG Lum, EM Jaffee, EGE De Vries… - Journal of Nuclear …, 2018 - Soc Nuclear Med
A workshop at the National Cancer Institute on May 2, 2016, considered the current state of
imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and …

[PDF][PDF] Indium-111–labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer

…, DT Sleijfer, PL Jager, EGE de Vries - Journal of clinical …, 2006 - Citeseer
… , Elisabeth GE de Vries Collection and assembly of data: Patrick J. Perik, Marjolijn N. Lub-de
Jager, Elisabeth GE de Vries Data analysis and interpretation: Patrick J. Perik, Marjolijn N. …

On the taxonomic status of Dugesia gonocephala and Dugesia subtentaculata (Turbellaria, Tricladida, Paludicola)

EJD Vries - Journal of Zoology, 1986 - Wiley Online Library
… in the aneuploids which cannot be matched into triplets (De Vries, In press). The basic
karyotype of the diploid populations corresponds to the typical D. gonocephulu karyotype (cf. …

[HTML][HTML] Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey

…, D Trapani, F Roitberg, EGE De Vries… - The Lancet …, 2021 - thelancet.com
Background The WHO Essential Medicines List (EML) identifies priority medicines that are
most important to public health. Over time, the EML has included an increasing number of …